Are there molecular signatures for predicting bladder cancer prognosis?

被引：7

作者：

Lokeshwar, Vinata B. ^{[1
]}

机构：

[1] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Dept Urol & Cell Biol & Anat, Miami, FL 33152 USA

来源：

JOURNAL OF UROLOGY | 2006年 / 176卷 / 06期

关键词：

D O I：

10.1016/j.juro.2006.08.142

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

引用

页码：2347 / 2348

页数：2

共 10 条

[1]

Bakkar AA, 2003, CANCER RES, V63, P8108

[2]

Droller M J, 1981, Curr Probl Surg, V18, P205, DOI 10.1016/S0011-3840(81)80002-0

[3]

Cellular signaling by fibroblast growth factor receptors [J].

Eswarakumar, VP ;

Lax, I ;

Schlessinger, J .

CYTOKINE & GROWTH FACTOR REVIEWS, 2005, 16 (02) :139-149

[4]

FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas:: Independent distribution and lack of association with prognosis [J].

Hernández, S ;

López-Knowles, E ;

Lloreta, J ;

Kogevinas, M ;

Jaramillo, R ;

Amorós, A ;

Tardón, A ;

García-Closas, R ;

Serra, C ;

Carrato, A ;

Malats, N ;

Real, FX .

CLINICAL CANCER RESEARCH, 2005, 11 (15) :5444-5450

[5]

Jones P A, 1993, Semin Urol, V11, P177

[6]

Genetic alterations in urothelial bladder carcinoma - An updated review [J].

Mhawech-Fauceglia, P ;

Cheney, RT ;

Schwaller, J .

CANCER, 2006, 106 (06) :1205-1216

[7]

Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection [J].

Rieger-Christ, KM ;

Mourtzinos, A ;

Lee, PJ ;

Zagha, RM ;

Cain, J ;

Silverman, M ;

Libertino, JA ;

Summerhayes, IC .

CANCER, 2003, 98 (04) :737-744

[8]

SPRUCK CH, 1994, CANCER RES, V54, P784

[9]

FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma [J].

van Rhijn, BSW ;

van der Kwast, TH ;

Vis, AN ;

Kirkels, WJ ;

Boevé, ER ;

Jöbsis, AC ;

Zwarthoff, EC .

CANCER RESEARCH, 2004, 64 (06) :1911-1914

[10]

Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome [J].

van Rhijn, BWG ;

Vis, AN ;

van der Kwast, TH ;

Kirkels, WJ ;

Radvanyi, F ;

Ooms, ECM ;

Chopin, DK ;

Boevé, ER ;

Jöbsis, AC ;

Zwarthoff, EC .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (10) :1912-1921

← 1 →